These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33854624)

  • 21. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
    Bear HD; Tang G; Rastogi P; Geyer CE; Zoon CK; Kidwell KM; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
    Ann Surg Oncol; 2017 Jul; 24(7):1853-1860. PubMed ID: 27864694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab.
    Jabeen S; Zucknick M; Nome M; Dannenfelser R; Fleischer T; Kumar S; Lüders T; von der Lippe Gythfeldt H; Troyanskaya O; Kyte JA; Børresen-Dale AL; Naume B; Tekpli X; Engebraaten O; Kristensen V
    Oncoimmunology; 2018; 7(11):e1457598. PubMed ID: 30377556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
    Yamamoto Y; Tamura R; Tanaka T; Ohara K; Tokuda Y; Miyake K; Takei J; Akasaki Y; Yoshida K; Murayama Y; Sasaki H
    Oncotarget; 2017 Nov; 8(61):103890-103899. PubMed ID: 29262608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
    Levin VA; Chan J; Datta M; Yee JL; Jain RK
    J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
    Trédan O; Follana P; Moullet I; Cropet C; Trager-Maury S; Dauba J; Lavau-Denes S; Diéras V; Béal-Ardisson D; Gouttebel M; Orfeuvre H; Stefani L; Jouannaud C; Bürki F; Petit T; Guardiola E; Becuwe C; Blot E; Pujade-Lauraine E; Bachelot T
    Ann Oncol; 2016 Jun; 27(6):1020-1029. PubMed ID: 26916095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
    Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
    Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
    Tipping M; Eickhoff J; Ian Robins H
    J Clin Neurosci; 2017 Oct; 44():101-106. PubMed ID: 28711289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.
    Ma X; Wang X; Huang J; Chen Y; Zhang J; Zhang B; Shi C; Liu L
    PLoS One; 2016; 11(8):e0160148. PubMed ID: 27579484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer.
    Arimoto A; Uehara K; Tsuzuki T; Aiba T; Ebata T; Nagino M
    Int J Clin Oncol; 2015 Oct; 20(5):935-42. PubMed ID: 25788218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study.
    Tolnay E; Ghimessy ÁK; Juhász E; Sztancsik Z; Losonczy G; Dombi P; Vennes Z; Helf L; Csada E; Sárosi V
    Oncol Lett; 2019 Feb; 17(2):1750-1760. PubMed ID: 30675234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy.
    Nakashima K; Murakami H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
    Mol Clin Oncol; 2016 Nov; 5(5):575-578. PubMed ID: 27900087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Li Q; Yan H; Zhao P; Yang Y; Cao B
    Sci Rep; 2015 Oct; 5():15746. PubMed ID: 26503902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
    von Minckwitz G; Loibl S; Untch M; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Gerber B; ; Gnauert K; Heinrich B; Prätz T; Groh U; Tanzer H; Villena C; Tulusan A; Liedtke B; Blohmer JU; Kittel K; Mau C; Potenberg J; Schilling J; Just M; Weiss E; Bückner U; Wolfgarten M; Lorenz R; Doering G; Feidicker S; Krabisch P; Deichert U; Augustin D; Kunz G; Kast K; von Minckwitz G; Nestle-Krämling C; Rezai M; Höß C; Terhaag J; Fasching P; Staib P; Aktas B; Kühn T; Khandan F; Möbus V; Solbach C; Tesch H; Stickeler E; Heinrich G; Wagner H; Abdallah A; Dewitz T; Emons G; Belau A; Rethwisch V; Lantzsch T; Thomssen C; Mattner U; Nugent A; Müller V; Noesselt T; Holms F; Müller T; Deuker JU; Schrader I; Strumberg D; Uleer C; Solomayer E; Runnebaum I; Link H; Tomé O; Ulmer HU; Conrad B; Feisel-Schwickardi G; Eidtmann H; Schumacher C; Steinmetz T; Bauerfeind I; Kremers S; Langanke D; Kullmer U; Ober A; Fischer D; Kohls A; Weikel W; Bischoff J; Freese K; Schmidt M; Wiest W; Sütterlin M; Dietrich M; Grießhammer M; Burgmann DM; Hanusch C; Rack B; Salat C; Sattler D; Tio J; von Abel E; Christensen B; Burkamp U; Köhne CH; Meinerz W; Graßhoff ST; Decker T; Overkamp F; Thalmann I; Sallmann A; Beck T; Reimer T; Bartzke G; Deryal M; Weigel M; Huober J; Weder P; Steffens CC; Lemster S; Stefek A; Ruhland F; Hofmann M; Schuster J; Simon W; Kronawitter U; Clemens M; Fehm T; Janni W; Latos K; Bauer W; Roßmann A; Bauer L; Lampe D; Heyl V; Hoffmann G; Lorenz-Salehi F; Hackmann J; Schlag R
    Ann Oncol; 2014 Dec; 25(12):2363-2372. PubMed ID: 25223482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1.
    Pan CF; Zhang X; Wang JW; Yang T; Zhong LLD; Shen KP
    Front Pharmacol; 2020; 11():512598. PubMed ID: 33746736
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.